PBYI
PUMA BIOTECHNOLOGY, INC.
$7.01
-0.50%
$358.8M
No data for this timeframe.
Vol
Market Cap$358.8M
Cap SizeSmall Cap
Inst. Holders9 funds
Inst. Value$40.5M
Inst. Activity2 buys / 0 sells
Reddit Sentiment50° Neutral
SEC Reports1
Recent Activity
May 7, 2026
earnings_calendar
PBYI Q1 2026 Earnings Scheduled — 2026-05-07
Feb 26, 2026
SEC
Puma Biotechnology reported fourth quarter and full year 2025 financial results with product revenue growth to $204.1 mi
8-K — Impact 6/10
Feb 18, 2026
Insider
AUERBACH ALAN H sold 159,778 shares
President and CEO @ $0.00 ($0.00)
Feb 18, 2026
Insider
AUERBACH ALAN H sold 227,474 shares
President and CEO @ $0.00 ($0.00)
Feb 18, 2026
Insider
HUNT DOUGLAS M sold 49,394 shares
See Remarks @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
162,351 shares ($966.0K)
Inst.
WELLS FARGO & COMPANY/MN — ADD
48,281 shares ($287.3K)
Price Targets
Historical data — last covering-analyst action Feb 2025. No current recommendation available.
$5.00 (Feb 2025)
Current $7.02
Low $5.00
Median $5.00
High $5.00
1 analysts
$5.00
$5.00
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 28, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Dec 23, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 20, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Nov 8, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Aug 2, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.07 | $0.07 — $0.07 | -53% YoY | 1 |
| Next Q | $0.19 ▼ -9.5% | $0.19 — $0.19 | -10% YoY | 1 |
| Current FY | $0.45 ▲ +12.5% | $0.45 — $0.45 | -40% YoY | 1 |
| Next FY | $0.35 ▼ -46.2% | $0.35 — $0.35 | -22% YoY | 1 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $22.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $12.6M | — |
| MORGAN STANLEY | $1.9M | — |
| FMR LLC | $975.0K | — |
| TWO SIGMA INVESTMENTS, LP | $966.0K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 18, 2026 | AUERBACH ALAN | A | $0.00 |
| Feb 18, 2026 | AUERBACH ALAN | A | $0.00 |
| Feb 18, 2026 | HUNT DOUGLAS | A | $0.00 |
| Feb 18, 2026 | HUNT DOUGLAS | A | $0.00 |
| Feb 18, 2026 | NOUGUES MAXIMO | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
9 institutional holders with $40.5M total value (6,813,904 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,797,748 | $22.6M | 55.7% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 2,123,813 | $12.6M | 31.2% | — |
| 3 | MORGAN STANLEY | 326,774 | $1.9M | 4.8% | — |
| 4 | FMR LLC | 163,870 | $975.0K | 2.4% | — |
| 5 | TWO SIGMA INVESTMENTS, LP | 162,351 | $966.0K | 2.4% | DOUBLED +189.3% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 125,372 | $746.0K | 1.8% | NEW |
| 7 | BANK OF AMERICA CORP /DE/ | 52,385 | $311.7K | 0.8% | TRIM -33.1% |
| 8 | WELLS FARGO & COMPANY/MN | 48,281 | $287.3K | 0.7% | ADD +48.4% |
| 9 | CAUSEWAY CAPITAL MANAGEMENT LLC | 13,310 | $79.2K | 0.2% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 56,126 | 162,351 | +189.3% | $966.0K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 32,531 | 48,281 | +48.4% | $287.3K | 2025-Q4 |
| UBS Group AG | ADD | 274,100 | 376,091 | +37.2% | $2.0M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 190,621 | 56,126 | -70.6% | $298.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 67,242 | 44,967 | -33.1% | $238.8K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 93,087 | 67,242 | -27.8% | $230.6K | 2025-Q2 |
| UBS Group AG | ADD | 155,571 | 279,667 | +79.8% | $827.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 180,725 | 32,900 | -81.8% | $97.4K | 2025-Q1 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | NEW | — | 14,095 | — | $41.7K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 43,989 | 180,725 | +310.8% | $551.2K | 2024-Q4 |
| UBS Group AG | DOUBLED | 27,094 | 155,571 | +474.2% | $474.5K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 16,803 | 22,929 | +36.5% | $69.9K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 117,666 | — | $300.0K | 2024-Q3 |
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | AUERBACH ALAN H | President and CEO | A | 159,778 | $0.00 | $0.00 |
| Feb 18, 2026 | AUERBACH ALAN H | President and CEO | A | 227,474 | $0.00 | $0.00 |
| Feb 18, 2026 | HUNT DOUGLAS M | See Remarks | A | 49,394 | $0.00 | $0.00 |
| Feb 18, 2026 | HUNT DOUGLAS M | See Remarks | A | 70,321 | $0.00 | $0.00 |
| Feb 18, 2026 | NOUGUES MAXIMO F | Chief Financial Officer | A | 46,739 | $0.00 | $0.00 |
| Feb 18, 2026 | NOUGUES MAXIMO F | Chief Financial Officer | A | 66,541 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2025): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2025. No current recommendation available.
$5.00 mean target (Feb 2025)
$5.00 Low
$5.00 High
| Metric | Value |
|---|---|
| Current Price | $7.02 |
| Target Low | $5.00 |
| Target Mean | $5.00 |
| Target Median | $5.00 |
| Target High | $5.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.07 | $0.07 | $0.07 | -53.3% | +0.0% | — | $0.1B | 1.1% | 1 |
| Next Q 2026-09-30 |
$0.19 | $0.19 | $0.19 | -9.5% | -9.5% | — | $0.1B | 11.9% | 1 |
| Current FY 2026-12-31 |
$0.45 | $0.45 | $0.45 | -40.0% | +12.5% | 1↑ 0↓ | $0.2B | -2.8% | 1 |
| Next FY 2027-12-31 |
$0.35 | $0.35 | $0.35 | -22.2% | -46.2% | 1↑ 0↓ | $0.2B | -1.4% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.070 | |
| 7d ago | $0.070 | |
| 30d ago | $0.070 | |
| 60d ago | $0.070 | |
| 90d ago | $0.120 | -0.050 |
14 analyst firms have rated this stock: 2 upgrades, 7 downgrades, 4 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 28, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Dec 23, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 20, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 26, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 20, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 13, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 20, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 4, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 5, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 5, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 6, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Aug 5, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| May 6, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Sep 28, 2021 | Citigroup | UPGRADE | Neutral | Buy |
| Aug 6, 2021 | RBC Capital | MAINTAIN | — | Sector Perform |
| Aug 6, 2021 | Goldman Sachs | MAINTAIN | — | Sell |
| Aug 10, 2020 | Citigroup | MAINTAIN | — | Neutral |
| Aug 7, 2020 | SVB Leerink | MAINTAIN | — | Market Perform |
| May 20, 2020 | Cantor Fitzgerald | MAINTAIN | — | Neutral |
| Dec 6, 2019 | HC Wainwright & Co. | INITIATE | — | Buy |
| Oct 8, 2019 | Goldman Sachs | DOWNGRADE | Neutral | Sell |
| Aug 9, 2019 | Barclays | MAINTAIN | — | Underweight |
| May 10, 2019 | Citigroup | DOWNGRADE | Buy | Neutral |
| May 10, 2019 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
| Mar 1, 2019 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 17, 2019 | Leerink Swann | INITIATE | — | Market Perform |
| Jan 3, 2019 | Guggenheim | DOWNGRADE | Buy | Neutral |
| Nov 19, 2018 | Goldman Sachs | UPGRADE | Sell | Neutral |
| Nov 2, 2018 | JP Morgan | MAINTAIN | Underweight | Underweight |
| Nov 2, 2018 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Nov 2, 2018 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
| Oct 1, 2018 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Sep 18, 2018 | Citigroup | MAINTAIN | Buy | Buy |
| Sep 17, 2018 | Goldman Sachs | INITIATE | — | Sell |
| Aug 10, 2018 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jun 28, 2018 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 12, 2018 | Barclays | DOWNGRADE | Overweight | Equal-Weight |
| Mar 9, 2018 | Stifel | MAINTAIN | Buy | Buy |
| Mar 2, 2018 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 24, 2018 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jan 24, 2018 | Credit Suisse | MAINTAIN | Outperform | Outperform |
| Jan 24, 2018 | B of A Securities | MAINTAIN | Buy | Buy |
| Jan 24, 2018 | Citigroup | MAINTAIN | Buy | Buy |
| Jan 24, 2018 | Cowen & Co. | DOWNGRADE | Outperform | Market Perform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 3 | 2 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 7, 2026
earnings_calendar
PBYI Q1 2026 Earnings Scheduled — 2026-05-07
Apr 30, 2026
earnings_calendar
PBYI Q1 2026 Earnings Scheduled — 2026-04-30
Feb 26, 2026
earnings_calendar
PBYI Q4 2025 Earnings After Market Close — 2026-02-26
Feb 24, 2026
Clinical Trial
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Phase Phase 2 — TERMINATED